Studies have demonstrated an enhancement in the anti-tumor response upon treatment with CDK4/6 inhibitors due to an enhancement in interferon production, reduced T-regs and enhanced T cell activation (251, 252). The gene discussed is CDK4; the disease is neoplasm.